报告原因：有业绩公布需要点评 增持（维持） 上 市 公 司 美容护理 2025 年 10 月 30 日 华熙生物 (688363) ——环比 25Q2 营收利润双改善，聚焦高质量发展 | 市场数据： 2025 年 10 月 29 日 | | | --- | --- | | 收盘价（元） | 53.93 | | 一年内最高/最低（元） | 69.50/42.51 | | 市净率 | 3.7 | | 股息率%（分红/股价） | 0.20 | | 流通 A 股市值（百万元） | 25,977 | | 上证指数/深证成指 4,016.33/13,691.38 | | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 09 月 30 日 | | --- | --- | | 每股净资产（元） | 14.66 | | 资产负债率% | 16.29 | | 总股本/流通 A 股（百万） | 482/482 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 10-29 11-29 12-29 01-29 02-28 03-31 04-30 05-31 06-3 ...

乐普医疗 20251026 摘要 乐普医疗传统业务稳健，心血管器械和仿药业务保持平稳，预计 2025 年基础业务利润可达 10 至 12 亿元。经营性现金流显著提升，前三季度 已达 10 亿元，预计全年可达 15 亿元。 医美板块成为业绩增长新引擎，童颜针已实现含税销售额近 1 亿元，并 进入 1,500 至 2000 家机构。热玛吉和 PDRN 产品预计明年一、二季度 上市，有望进一步提升医美板块收入。 集采政策对心血管器械带来压力，公司通过调整经销商库存和积极参与 集采应对。冠脉切割球囊可能面临损失，但辅助球囊有望实现增量，整 体保持平衡。 乐普医疗积极拓展医美市场，采取"农村包围城市"策略，已覆盖 80% 的开一店，并计划进一步扩大覆盖范围，通过与美团等平台合作提高市 场份额。 创新药研发取得显著进展，109 号药物已完成二期临床，计划明年进入 三期临床。减重、降脂、降压等多个创新药项目也在积极推进中，为未 来发展提供多种可能性。 Q&A 乐普医疗在 2025 年第三季度的业绩表现如何？ 乐普医疗在 2025 年第三季度实现了收入同比增长接近 12%，净利润增长 176%，达到 2.9 亿元。前三季度的 ...

当PDRN成分席卷美妆市场时，与之相关的14大衰老标志之一的「线粒体抗衰」却仍未迎来爆发时刻。这座掌控95%细胞能量的「生命工厂」，为何难以叩 开消费者的认知大门？但美妆巨头们的科研竞赛，正把战场推向细胞能量的最深处。 深度科普：线粒体功能障碍如何导致皮肤衰老？ 在微观的世界里，线粒体的"一呼一吸"对皮肤乃至整个人体的健康产生重要的影响。 早在2013年，《Cell》期刊便将"线粒体功能障碍"列为衰老的九大标志物之一，推动其研究从狭义的线粒体DNA（mtDNA）遗传病拓展至广义的与线粒体功 能障碍相关的疾病谱研究。线粒体作为皮肤细胞的能量工厂，为细胞活动提供95%的能量货币ATP，而皮肤抗氧化的核心——自由基（ROS）同样是能量生 产活动的副产物。 但想要入局线粒体抗老这一前沿技术赛道，首先要了解线粒体的工作和生存机制。 作为细胞呼吸的关键参与者和能量生产的"能量工厂"，双膜结构细胞器——线粒体对于维持细胞生存和发挥正常生理作用至关重要。 线粒体通过电子传递链（ETC）和三羧酸循环，将有机物质如葡萄糖等被氧化产生大量的三磷酸腺苷（Adenosine Triphosphate，ATP）[1]。 同时，线粒体还有 ...

Core Viewpoint - The report from CITIC Securities indicates that leading global medical aesthetics companies with established brand strength, proactive global channel expansion, and product innovation are expected to achieve superior growth by Q2 2025 [1] Group 1: Market Dynamics - In the U.S., middle-class demand may continue to face pressure, while competition in the South Korean market is intensifying [1] - Emerging markets in China, Europe, and globally are showing steady growth, contributing positively to the medical aesthetics sector [1] Group 2: Product Trends - Leading companies in botulinum toxin are experiencing more stable growth, with market dynamics shifting towards top-tier players [1] - There is a diversification in filler product categories, with hyaluronic acid facing ongoing pressure, while regenerative materials/PDRN are maintaining high growth [1] - In the equipment category, strong brand products in radiofrequency and ultrasound are expected to sustain their momentum [1] Group 3: Future Outlook - Companies that actively expand globally and invest in new materials and product categories are likely to exhibit strong growth potential and may revise their performance guidance upwards [1] - Regional companies focusing on mature markets may face challenges due to intensified competition and operational pressures [1] - The industry outlook remains positive for leading medical aesthetics companies with established brand presence, as they leverage regional and product category expansions for superior growth [1]

Summary of the Medical Aesthetics and Cosmetics Industry Conference Call Industry Overview - The medical aesthetics industry in China has a significantly lower penetration rate compared to the US and South Korea, indicating substantial growth potential. The current penetration rate is approximately 2 per 1,000 people, while the US and South Korea have rates of 5‰ and 8‰ respectively, suggesting a large market opportunity for growth [2][3][4] - The consumer repurchase rate for medical aesthetics is high, with stable demand for light medical aesthetics services, which provides a solid foundation for industry development [2][3] Market Dynamics - The medical aesthetics industry is divided into two main segments: medical aesthetics and cosmetics. The medical aesthetics segment remains robust post-pandemic, with a focus on product and material development [3][4] - The upstream raw material sector has high gross margins, with companies like Aimeike achieving margins of 85%-90%. The typical markup at the consumer level is over three times the factory price, ensuring profitability for institutions and sales personnel [2][4] Capital Market Trends - Capital markets are increasingly focused on upstream manufacturers, particularly the transition from hyaluronic acid to active materials such as recombinant collagen and PDRN. This shift is driven by rising consumer demand for facial treatments [7] - The market for light medical aesthetics accounts for approximately 70% in leading hospitals, with new medical aesthetics primarily divided into photonic and injection categories [8] Product Market Size - The market size for hyaluronic acid and botulinum toxin at the factory level is estimated to be between 50 to 100 billion yuan. The markup for mature products typically ranges from 2 to 3 times, with high-end products potentially reaching 3 to 4 times [9] - The regenerative materials market has seen rapid growth, with several companies achieving sales exceeding 1 billion yuan since 2021. However, these materials are not fully replacing hyaluronic acid but rather expanding the market [10][11] Material Development and Trends - The development of regenerative materials is significant, with a focus on micro-spheres that stimulate natural repair and collagen regeneration. These materials are expected to enhance treatment effectiveness and safety in soft tissue filling and skin management [15][16] - The future of the medical aesthetics industry is expected to shift towards active micro-spheres and humanized collagen, with a focus on extracellular matrix and various collagen types [15] Cosmetics Industry Overview - The cosmetics industry has seen a clear trend towards domestic brand replacement, with domestic brands now accounting for over 50% of the market. Brands are leveraging e-commerce and live streaming to enhance growth, with increased R&D investments focusing on efficacy and ingredient-driven strategies [2][21] - The market has shifted from high-end luxury products to a broader consumer base, with skincare products maintaining steady growth despite the pandemic [21][22] Sales Dynamics - The sales of domestic cosmetics exhibit seasonal variations, with the first half of the year accounting for about 40% of total sales and the second half for 60%. Major shopping events like 618 and Double Eleven significantly impact annual sales [24] R&D Investment Differences - There is a notable difference in R&D investment between the medical aesthetics and cosmetics industries. The medical aesthetics sector focuses on material iteration, while the cosmetics industry emphasizes brand building and marketing to enhance consumer loyalty [25] Future Outlook - The future of domestic cosmetics companies appears optimistic, with expectations of revenue growth driven by channel changes and ingredient innovations. Companies like Perfect Diary and Proya are projected to reach revenue levels of 20 to 30 billion yuan in the next 3 to 5 years [30]

Core Insights - The Chinese medical beauty market is projected to reach a scale of 265 billion yuan by 2024, with a CAGR of 15% from 2017 to 2024 [1] - The number of medical beauty consumers in China is expected to reach 31 million by 2024, with a CAGR of 9% from 2022 to 2024 [1] - The average number of medical beauty treatments per person in China is significantly lower than in developed markets such as South Korea, the United States, and Japan, indicating substantial growth potential [1] Industry Growth Potential - The medical beauty industry is anticipated to maintain steady growth in the high single digits over the next three years, with notable structural opportunities [1] - Certain medical beauty materials still present track dividends, particularly in areas such as natural and recombinant collagen, regenerative microspheres, and emerging materials like PDRN, ECM, silk protein, and PHA [1] - Companies with platform capabilities in upstream product development and downstream medical beauty institutions that possess high reputation and integrated resources are expected to thrive [1]

Core Insights - The skincare industry in China is experiencing high growth driven by ingredient transparency and scientifically validated efficacy, with domestic brands leveraging synthetic biology and targeted ingredient development to gain competitive advantages [1][2][3] Group 1: Market Trends - The Chinese skincare market is transitioning to an era of ingredient transparency and scientifically verifiable efficacy, with consumers shifting from brand reliance to rational analysis of ingredient lists [1] - The overall market size for cosmetics in China is projected to reach 774.6 billion yuan in 2024, reflecting a year-on-year decline of 2.83%, while the efficacy skincare segment is expected to grow significantly, surpassing 100 billion yuan [1] - The compound annual growth rate (CAGR) for efficacy skincare products from 2019 to 2024 is estimated at 24.9%, with this segment expected to account for 22.9% of the total skincare market by 2024 [1] Group 2: Product Development and Innovation - The targeted ingredient development has led to a multi-channel synergy for three core functions: anti-wrinkle and firming through peptides and other compounds, soothing and repairing through ingredients like centella asiatica and ceramides, and hydration through amino acids and hyaluronic acid [2] - Domestic brands such as Proya and Winona have entered the top 10 in the high-end anti-aging and soothing markets, traditionally dominated by international brands [2] - The evolution of ingredient formulations has progressed from basic hydration to synthetic biology, with Chinese companies achieving technological advancements, such as Huaxi Biological's breakthrough in hyaluronic acid and the establishment of international standards for recombinant collagen [3] Group 3: Emerging Opportunities - The rise of domestic brands is characterized by cost-effective ingredient innovations and technological differentiation, particularly in the peptide segment, where brands like Proya and Han Shu are reshaping the anti-aging landscape [3] - Traditional Chinese medicine ingredients are becoming core competitive advantages, with significant online sales growth projected for ginseng, astragalus, and artemisia, indicating a strong market for local herbal formulations [3]

Summary of Conference Call Records Industry or Company Involved - The records cover various industries including macroeconomic trends, coal, healthcare, technology, and financial services. Specific companies mentioned include 乐普医疗 (Lepu Medical), 银河医疗 (Yinhe Medical), and 九方智投控股 (Jiufang Zhitu Holdings). Key Points and Arguments Macroeconomic Trends - The economic outlook remains stable, with potential price increases indicated by July's PMR data, suggesting a positive trend for August [1] - Attention is drawn to the easing of tariffs in the US-China trade negotiations, although uncertainties remain regarding the final outcomes [2][3] - The US economy shows resilience, with expectations of continued monetary policy adjustments [2][3] Market Sentiment - The market is expected to remain cautious in August, with potential corrections following previous optimistic expectations [4][5] - The index is projected to stabilize between 3,400 and 3,500 points, influenced by demand stimulation in sectors like robotics and consumption [4] Sector-Specific Insights - **Healthcare**: - 乐普医疗 is highlighted for its strong growth potential, particularly with its new product launches and market strategies aimed at capturing low-price segments [12][13][14] - The company is expected to achieve significant revenue growth, with projections of 40 to 50 billion in actual sales potential [13] - **Coal Industry**: - The coal sector is experiencing policy-driven price support, with expectations of price stabilization due to supply constraints [16][17] - Focus on焦煤 (coking coal) prices shows a significant rebound, with current prices rising from 1,200 to over 1,650 [18] - **Technology**: - The domestic AI sector is anticipated to grow, driven by increased demand for computing power and advancements in local technology [36][37] - Companies like 天湖通信 (Tianhu Communication) are positioned to benefit from the transition to 1.6T technology, with confirmed orders indicating strong future growth [39] - **Financial Services**: - 九方智投控股 is noted for its unique position in the financial information service sector, with a limited number of licenses available, enhancing its market potential [28][29] - The company is expected to benefit from increasing demand for investment education and advisory services as traditional investment channels shrink [28] Other Important Insights - The healthcare sector is seeing a shift towards new consumption patterns, with a focus on innovative products that meet emerging market needs [11][12] - The coal market is under scrutiny for its response to environmental policies, with expectations of price support mechanisms to stabilize the market [16][17] - The technology sector is experiencing a significant transformation, with AI and computing power becoming critical drivers of growth [36][37] Conclusion - The overall sentiment across various sectors indicates cautious optimism, with specific companies positioned to leverage market trends and policy changes for growth. The focus remains on innovation, market adaptability, and strategic positioning in response to evolving consumer demands and regulatory landscapes.

Core Viewpoint - The report from CITIC Securities highlights the significant growth potential in China's medical aesthetics industry, driven by increasing awareness and an aging customer base, with injectable products expected to outpace overall industry growth due to supply-side improvements [1] Market Growth - Despite short-term pressures, the long-term outlook for the medical aesthetics market is positive, with a projected terminal scale exceeding 230 billion yuan in 2023 and a CAGR of 10%-15% from 2024 to 2027; injectables are expected to grow at a CAGR of 20%-30% over the next five years [1] - The report indicates that the number of medical aesthetic treatments per thousand people in South Korea, Japan, and China are 91 (2019), 71 (2023E), and 34 (2023E) respectively, suggesting significant room for growth driven by increased awareness and an aging population [1] Development Trends - The competitive landscape for products is expected to evolve into a U-shaped pattern, with initial high concentration due to regulatory barriers, followed by increased competition, and ultimately a return to higher concentration as operational capabilities differentiate companies [2] - The medical aesthetics industry is characterized by "limited innovation," making operational capabilities increasingly important; leading companies are expected to benefit from their established operational strengths [2][3] Investment Recommendations - There are opportunities for product breakthroughs, particularly in non-hyaluronic acid materials, with over 110 approved injectable products in China, and limited competition in other categories; new product approvals, especially in botulinum toxin and other innovative materials, are anticipated to drive market growth [2] - The report emphasizes the importance of comprehensive operational capabilities, with leading companies expected to maintain their competitive edge in a market characterized by limited innovation [3]

Core Viewpoint - The beauty industry is experiencing a surge in interest in PDRN (Polydeoxyribonucleotide), with numerous domestic and international brands launching products featuring this ingredient, indicating a promising market outlook for PDRN in the coming years [2][3][5]. Group 1: Market Trends and Growth - The global PDRN market was approximately 180 million yuan in 2023 and is expected to reach 3 billion yuan by 2030, with a compound annual growth rate (CAGR) of 43% from 2024 to 2030 [2]. - Currently, there are 3,894 brands using PDRN, with 16,901 products containing this ingredient, showing rapid growth in the market [5]. - The PDRN market is characterized by a diverse range of players, including domestic brands like Zhanmei Ya and international giants like L'Oréal and Amorepacific, all actively entering the PDRN space [2][6][13]. Group 2: Product Innovations and Technologies - Zhanmei Ya's "Ball PDRN Energy Stick" achieved over 10 million in sales within a month of launch, highlighting the strong consumer demand for PDRN products [7]. - Various brands are employing innovative technologies to enhance PDRN's effectiveness, such as microencapsulation and lactobacillus vesicle technology, to improve skin absorption [29][30]. - PDRN is being integrated into a wide range of products, including serums and creams, with brands like CNP and Lancôme emphasizing its clinical-grade efficacy [9][11][30]. Group 3: Scientific Basis and Mechanisms - PDRN has a long history of use in the beauty industry, with established benefits in skin repair and regeneration, supported by over 600 research publications [14][23]. - The mechanism of PDRN involves promoting cell proliferation and regulating inflammatory responses, making it a valuable ingredient for anti-aging and skin repair [23][24]. - PDRN's unique properties, such as its non-antigenic nature and low toxicity, contribute to its safety and effectiveness in cosmetic applications [21][23]. Group 4: Challenges and Future Prospects - Despite its popularity, PDRN faces challenges related to its large molecular size and poor transdermal absorption, which are critical for its effectiveness in topical applications [29][30]. - The market is witnessing a trend towards artificial synthesis of PDRN, which could enhance production consistency and reduce costs, making it more accessible [39][41]. - As the market matures, there is a need for better consumer education regarding PDRN's benefits and limitations to avoid misconceptions about its efficacy [33][35].